Evidence map›Paper›PMID 37969958›Full record

ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2023

Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.

Jianwei Zhang, Haibin Zhu, Lin Shen, Jie Li, Xiaoyan Zhang, Chunmei Bai, Zhiwei Zhou, Xianrui Yu, Zhiping Li, Enxiao Li and 18 more

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02589821 (A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02589821 phase3completednot on this map

A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors

TypeinterventionalSponsorHutchison Medipharma LimitedRan2015 to 2022Enrolled195ConditionsNeuroendocrine TumorsArmsSurufatinib, Placebo
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 1 country.

Jianwei ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Haibin ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Lin ShenState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Jie LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Xiaoyan ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Chunmei BaiDepartment of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhiwei ZhouDepartment of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510062, China.
Xianrui YuDepartment of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Zhiping LiDepartment of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu 332001, China.
Enxiao LiDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Xianglin YuanDepartment of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Wenhui LouDepartment of General Surgery, Zhongshan Hospital of Fudan University, Shanghai 200032, China.
Yihebali ChiDepartment of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Nong XuDepartment of Medical Oncology, the First Affiliated Hospital of Zhejiang University, Hangzhou 310009, China.
Yongmei YinDepartment of Medical Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Yuxian BaiDepartment of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin 150081, China.
Tao ZhangDepartment of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Dianrong XiuDepartment of General Surgery, Peking University Third Hospital, Beijing 100191, China.
Jia ChenDepartment of Medical Oncology, Jiangsu Cancer Hospital, Nanjing 214206, China.
Shukui QinCancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing 210016, China.
Xiuwen WangDepartment of Medical Oncology, Qilu Hospital of Shandong University, Jinan 250012, China.
Yujie YangDepartment of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China.
Haoyun ShiDepartment of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China.
Xian LuoDepartment of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China.
Songhua FanDepartment of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China.
Weiguo SuDepartment of Clinical and Regulatory Affairs, HUTCHMED Limited, Shanghai 200001, China.
Ming LuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Jianming XuDepartment of Gastrointestinal Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China.
Peking University · CNPeking University Cancer Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFudan University · CNFudan University Shanghai Cancer Center · CNHuazhong University of Science and Technology · CNJiangsu Province Hospital · CNPeking Union Medical College Hospital · CNPeking University Third Hospital · CNQilu Hospital of Shandong University · CNThird Affiliated Hospital of Harbin Medical University · CNTongji Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Currently, pre-treatment prediction of patients with pancreatic neuroendocrine tumors with liver metastases (PNELM) receiving surufatinib treatment was unsatisfying. Our objective was to examine the association between radiological characteristics and efficacy/prognosis. Methods: We enrolled patients with liver metastases in the phase III, SANET-p trial (NCT02589821) and obtained contrast-enhanced computed tomography (CECT) images. Qualitative and quantitative parameters including hepatic tumor margins, lesion volumes, enhancement pattern, localization types, and enhancement ratios were evaluated. The progression-free survival (PFS) and hazard ratio (HR) were calculated using Cox's proportional hazard model. Efficacy was analyzed by logistic-regression models. Results: Among 152 patients who had baseline CECT assessments and were included in this analysis, the surufatinib group showed statistically superior efficacy in terms of median PFS compared to placebo across various qualitative and quantitative parameters. In the multivariable analysis of patients receiving surufatinib (N=100), those with higher arterial phase standardized enhancement ratio-peri-lesion (ASER-peri) exhibited longer PFS [HR=0.039; 95% confidence interval (95% CI): 0.003-0.483; P=0.012]. Furthermore, patients with a high enhancement pattern experienced an improvement in the objective response ratio [31.3% Conclusions: These pre-treatment radiological features, namely high ASER-peri, high enhancement pattern, and well-defined tumor margins, have the potential to serve as predictive markers of efficacy in patients with PNELM receiving surufatinib.

Indexed as

computed tomographyliver metastasesNeuroendocrine tumorssurufatinib

Identifiers

PMID37969958
PMCPMC10643338
OpenAlexW4388676099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.